DE60205481T2 - Furan and thiophen-derivate die menschliche peroxisome proliferator aktivierte rezeptoren aktivieren - Google Patents

Furan and thiophen-derivate die menschliche peroxisome proliferator aktivierte rezeptoren aktivieren Download PDF

Info

Publication number
DE60205481T2
DE60205481T2 DE60205481T DE60205481T DE60205481T2 DE 60205481 T2 DE60205481 T2 DE 60205481T2 DE 60205481 T DE60205481 T DE 60205481T DE 60205481 T DE60205481 T DE 60205481T DE 60205481 T2 DE60205481 T2 DE 60205481T2
Authority
DE
Germany
Prior art keywords
methyl
phenyl
trifluoromethyl
acetic acid
thio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60205481T
Other languages
German (de)
English (en)
Other versions
DE60205481D1 (de
Inventor
Paul John Stevenage BESWICK
Christopher Charles Frederick Stevenage HAMLETT
Vipulkumar Stevenage PATEL
Michael Lawrence 25 SIERRA
Nigel Grahame Stevenage RAMSDEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of DE60205481D1 publication Critical patent/DE60205481D1/de
Publication of DE60205481T2 publication Critical patent/DE60205481T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60205481T 2001-05-11 2002-05-09 Furan and thiophen-derivate die menschliche peroxisome proliferator aktivierte rezeptoren aktivieren Expired - Fee Related DE60205481T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0111523.7A GB0111523D0 (en) 2001-05-11 2001-05-11 Chemical compounds
GB0111523 2001-05-11
PCT/GB2002/002152 WO2002092590A1 (en) 2001-05-11 2002-05-09 Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors

Publications (2)

Publication Number Publication Date
DE60205481D1 DE60205481D1 (de) 2005-09-15
DE60205481T2 true DE60205481T2 (de) 2006-05-24

Family

ID=9914442

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60205481T Expired - Fee Related DE60205481T2 (de) 2001-05-11 2002-05-09 Furan and thiophen-derivate die menschliche peroxisome proliferator aktivierte rezeptoren aktivieren

Country Status (20)

Country Link
US (1) US7091237B2 (OSRAM)
EP (1) EP1392674B1 (OSRAM)
JP (1) JP2004534035A (OSRAM)
KR (1) KR20040023600A (OSRAM)
CN (1) CN1507442A (OSRAM)
AT (1) ATE301649T1 (OSRAM)
BR (1) BR0209468A (OSRAM)
CA (1) CA2446797A1 (OSRAM)
CO (1) CO5540343A2 (OSRAM)
CZ (1) CZ20033064A3 (OSRAM)
DE (1) DE60205481T2 (OSRAM)
ES (1) ES2247322T3 (OSRAM)
GB (1) GB0111523D0 (OSRAM)
HU (1) HUP0304051A3 (OSRAM)
IL (1) IL158332A0 (OSRAM)
MX (1) MXPA03010285A (OSRAM)
NO (1) NO20034986L (OSRAM)
PL (1) PL367478A1 (OSRAM)
WO (1) WO2002092590A1 (OSRAM)
ZA (1) ZA200308352B (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
GB0113232D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical process
MXPA04001258A (es) 2001-08-10 2005-06-06 Nippon Chemiphar Co Activador para el receptor d que responde al proliferador de peroxisoma.
ITRM20020014A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
JP2005035966A (ja) * 2002-09-06 2005-02-10 Takeda Chem Ind Ltd フランまたはチオフェン誘導体およびその医薬用途
US7960369B2 (en) * 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
AU2003296402A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Thiophene derivative ppar modulators
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1493739A1 (fr) * 2003-07-03 2005-01-05 Warner-Lambert Company LLC Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
KR20080042188A (ko) 2003-11-05 2008-05-14 에프. 호프만-라 로슈 아게 Ｐｐａｒ 작용제로서 페닐 유도체
WO2005063729A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
EP1698624B1 (en) 2003-12-26 2012-06-27 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
GB0403148D0 (en) * 2004-02-12 2004-03-17 Smithkline Beecham Corp Chemical compounds
DE602004004631D1 (de) 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
EP1854784A1 (en) * 2005-02-28 2007-11-14 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator activating receptor
WO2006121223A1 (en) * 2005-05-07 2006-11-16 Heon Joong Kang Process for preparing ligands of ppardelta and the intermediate compounds for preparing the same
KR20080014075A (ko) * 2005-05-25 2008-02-13 닛뽕 케미파 가부시키가이샤 페록시좀 증식제 활성화 수용체의 활성화제
EP1931337B1 (en) 2005-09-29 2013-10-23 Sanofi Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
AU2006299092A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl-(1,2,4)-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
WO2007127502A2 (en) * 2006-01-10 2007-11-08 Smithkline Beecham Corporation Polymorphic form of { 2-methyl-4- [ 4-methyl-2- ( 4-triflu0r0methylphenyl) thiazol -5- ylmethylthiol phenoxy }-acetic acid
RU2435764C2 (ru) 2006-04-18 2011-12-10 Ниппон Кемифар Ко., Лтд. АГЕНТ, АКТИВИРУЮЩИЙ РЕЦЕПТОР, АКТИВИРУЕМЫЙ ПРОЛИФЕРАТОРАМИ ПЕРОКСИСОМ δ
KR101467590B1 (ko) * 2006-08-22 2014-12-01 랜박시 래보러터리스 리미티드 매트릭스 메탈로프로테나제 저해제
FR2910894A1 (fr) * 2006-12-29 2008-07-04 Genfit Sa Derives de 3-phenyl-1-(phenylthienyl)propan-1-one et de 3-phenyl-1-(phenylfuranyl)propan-1-one substitues, preparation et utilisation.
CA2672420A1 (en) 2006-12-29 2008-07-10 The Salk Institute For Biological Studies Methods for enhancing exercise performance
EA200970793A1 (ru) * 2007-02-23 2010-02-26 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом
GB2460784A (en) * 2007-03-07 2009-12-16 Dong A Pharmtech Co Ltd Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition
DE102008007400A1 (de) * 2008-02-04 2009-08-06 Bayer Healthcare Ag Substituierte Furane und ihre Verwendung
AU2009236877B2 (en) 2008-04-15 2014-01-23 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-activated receptor
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
WO2012030165A2 (ko) 2010-08-31 2012-03-08 서울대학교산학협력단 P P A R δ 활성물질의 태자재프로그래밍용도
US10118922B2 (en) * 2013-03-14 2018-11-06 Janssen Pharmaceutica Nv GPR120 agonists for the treatment of type II diabetes
CN105209450B (zh) * 2013-03-14 2017-10-20 美国陶氏益农公司 具有一定农药效用的分子和中间体、组合物及其相关方法
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9817118D0 (en) 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
RU2267484C2 (ru) 1999-04-28 2006-01-10 Авентис Фарма Дойчланд Гмбх Производные диариловой кислоты и фармацевтическая композиция на их основе

Also Published As

Publication number Publication date
HUP0304051A2 (hu) 2004-04-28
ATE301649T1 (de) 2005-08-15
US20040157890A1 (en) 2004-08-12
NO20034986D0 (no) 2003-11-10
BR0209468A (pt) 2004-08-03
GB0111523D0 (en) 2001-07-04
EP1392674A1 (en) 2004-03-03
NO20034986L (no) 2003-11-10
CN1507442A (zh) 2004-06-23
PL367478A1 (en) 2005-02-21
KR20040023600A (ko) 2004-03-18
CZ20033064A3 (cs) 2004-02-18
EP1392674B1 (en) 2005-08-10
ZA200308352B (en) 2005-01-27
CA2446797A1 (en) 2002-11-21
HUP0304051A3 (en) 2005-11-28
JP2004534035A (ja) 2004-11-11
ES2247322T3 (es) 2006-03-01
WO2002092590A1 (en) 2002-11-21
MXPA03010285A (es) 2004-03-09
US7091237B2 (en) 2006-08-15
DE60205481D1 (de) 2005-09-15
IL158332A0 (en) 2004-05-12
CO5540343A2 (es) 2005-07-29

Similar Documents

Publication Publication Date Title
DE60205481T2 (de) Furan and thiophen-derivate die menschliche peroxisome proliferator aktivierte rezeptoren aktivieren
DE60110262T2 (de) Thiazol und oxazol-derivate als aktivatoren von menschlichen peroxisom proliferator aktivierten rezeptoren
DE60124302T2 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60120217T2 (de) Thia- und oxazole und deren verwendung als ppars-aktivatoren
DE60010333T2 (de) Substituierte oxazole und thiazole derivate als hppar-alpha aktivatore
DE60223245T2 (de) Thiazol- und oxazolderivate, die sich für die behandlung von herzkreislauferkrankungen und ähnlichen erkrankungen eignen
DE60020701T2 (de) Thiazol- und oxazol-derivate und ihre pharmazeutische verwendung
EP1513526B1 (en) Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
AU2002246713A1 (en) Thiazole derivatives for treating PPAR related disorders
DE60223805T2 (de) Oxazol/thiazol-derivate als aktivatoren des hppar-alpha-rezeptors
DD210908A5 (de) Verfahren zur herstellung von ketenthioacetaten
US7141591B2 (en) 1,2,4-oxadiazole derivatives as hPPAR alpha agonists
US7439259B2 (en) Thiazole derivatives for treating PPAR related disorders
US7229998B2 (en) Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
WO2005037804A1 (en) Thiazole-2-carboxamide derivatives for use as hppar agonists in the treatment of i.a. dyslipidemia
AU2002253385A1 (en) Furan and thiophene derivatives that activate human peroxisome proliferator actvated receptors
HK1076712B (en) Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
HK1059925B (en) Thiazole derivatives for treating ppar related disorders

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee